Abstract
- Population : Immunocompetent children aged 3–24 months
- Intervention: One or two doses of MenA conjugate vaccine (5 µg dosage)
- Comparison: No MenA vaccination
- Outcome : Serious adverse events following immunization
What is the incidence of serious adverse events following any dose of MenA conjugate vaccine in immunocompetent children aged 3–24 months?
- GRADE table
- Newborn
- GRADE
- meningitis A
- Meningococcal disease
